Wednesday, July 8, 2026

biotech · Non-Small Cell Lung Cancer · Pneumococcal Vaccines · MAIA

MAIA Biotechnology

Makai Biotechnology is a biotech organization headquartered in honolulu, USA. It trades on NYSE under ticker MAIA. Primary therapeutic focus areas include Non-Small Cell Lung Cancer, Pneumococcal Vaccines, Carcinoma, Non

honolulu, USA HQ
2013 Founded
5 Employees
Public company Type
MAIA · NYSE Ticker
Company details
Clinical program

ateganosine

Phase 1 · small molecule · Resectable Hepatocellular Carcinoma

ateganosine for Resectable Hepatocellular Carcinoma is a Phase 1 program (small_molecule) at MAIA Biotechnology with 1 ClinicalTrials.gov record(s).

← All MAIA Biotechnology projects Phase 1 small molecule active

Internal code SCCC-12225; STU20251351

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
MAIA Biotechnology
Phase
Phase 1
Modality
small_molecule
Indication
Resectable Hepatocellular Carcinoma
Status
active
Trials
1

Clinical trials